Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - REGI U.S. Inc. - Exhibit 4.1

Exhibit 4.1

MODIFICATION 2

The Rand CamTM UAV Engine License agreement between
  Reg and Radian issued April 24, 2002, and modified May 14, 2004, is modified
  as follows:

1. The following is added to paragraph III (c) :

The Phase 2 Study is hereby ended. As consideration for this
  early close-out, Radian will provide the engineering work performed on the second
  prototype engine to REG without limitation. This includes study notes, drawings,
  parts lists, the preliminary patent application and the RadMaxTM
  trademark.

In exchange for this property, REG will provide an unconditional
  release to Radian for all obligations under the UAV license.

2. Paragrapoh III (e) is modified as follows:

Delete the words “this Modification 1” and substitute
  “Modification 2”

This Modification is effective as of the last date written below:

	REGI U.S., Inc. 	  
	Reg Technologies, Inc. 	  
	Rand Energy Group, Inc. 	Radian Inc. 
	  	  
	By: /s/ John Robertson 	By: /s/ Jerry Mailey 
	         John Robertson,
      President 	       Jerry Mailey, Director
      of Contracts 
	  	  
	Date: December 21, 2005 	Date: September 12, 2005Filed by Automated Filing Services Inc. (604) 609-0244 - ALDA Pharmaceuticals Corp. - Exhibit 4a

LETTER OF AGREEMENT

THIS AGREEMENT ("Agreement") is entered into and effective as
of July 21, 2005,

BEWEEN:

ALDA PHARMACEUTICALS
CORP., 635 Columbia Street, New Westminster, British Columbia V3M 1A7
CANADA

(“ALDA”)

AND:

PHIGENICS, LLC, 735
Thornapple Dr., Naperville, IL, 60540 USA 

(“PHIGENICS”)

WHEREAS ALDA has developed a disinfectant product known as
T36® Disinfectant (“T36D”, also currently known as
Viralex) for broad spectrum surface disinfection and

WHEREAS PHIGENICS is interested in:

	assisting ALDA with the registration of T36D with the US Environmental
  Protection Agency (“EPA”),
  
	working with ALDA Pharmaceuticals Corp. to develop new formulations of
  T36D and
  
	developing sales and distribution channels in the US, 

IT IS AGREED THAT:

	1. 	
      PHIGENICS will act on behalf of ALDA to register ALDA’s
      T3 6® Disinfectant (“T36D”, currently known as
      “Viralex”) with the EPA (“the Registration”).

	2. 	
      The estimated budget for the Registration is US$65,000 or
      less, comprised of no more than US$32,000 cash expenditures and a
      contribution in kind of US$33,000 by Dr. William F. McCoy (“WFM”) at an
      agreed upon rate per diem.

	3. 	
      PHIGENICS will obtain advance approval from ALDA for any
      cash expenditures referred to in Paragraph 2.

	4. 	
      ALDA will provide all possible assistance that PHIGENICS
      requires for the Registration. within capabilities of ALDA.

	5. 	
      In return for assisting with the Registration, PHIGENICS
      will receive a royalty on Net Sales (gross sales less refunds and returns)
      of T36D in the US starting 90 days after the Registration is achieved, as
      follows:

		a. 	
      7% for the first year up to 150% of WFM's contribution in
      kind has been repaid and then 5% for the remainder of the first
    year.

		b. 	
      5% for the second year.

		c. 	
      4% for the third year.

		d. 	
      3% for the fourth year.

		e. 	
      2% for the fifth year.

	 	f. 	
      1% for the sixth and seventh
years.

	6. 	
      It is understood that ALDA has its own personnel who are
      prepared to undertake sales and marketing activities in the US. However,
      if PHIGENICS introduces ALDA to prospects unknown to ALDA from which sales
      result, PHIGENICS will be paid a finder’s fee of 5% of sales to that
      client for the first year after the first sale and 3% for the next
      year.

	 	 
	7. 	
      ALDA and PHIGENICS will jointly develop a research
      program at a later date.

The terms above are accepted by:

ALDA PHARMACEUTICALS CORP.
Per:

	“Terrance G. Owen”
    	 
	Terrance G. Owen, President & CEO 	 

AND

PHIGENICS, LLC
Per:

	“William F. McCoy”
    	 
	William F. McCoy, Chief Technology OfficerFiled by Automated Filing Services Inc. (604) 609-0244 - ALDA Pharmaceuticals Corp. - Exhibit 4b

AGREEMENT

This agreement (“Agreement”) is entered into as of the
4th day of October, 2005,

BETWEEN:

                NORWOOD
  PACKAGING LTD., 8519 – 132nd Street, Surrey, BC, V3W 4N8 (“Norwood”)

AND:

                ALDA
Pharmaceuticals Corp. of 635 Columbia Street, New Westminster, BC V3M 1A7
(“ALDA”).

WHEREAS ALDA has developed a disinfectant product known as
T36® Disinfectant (“T36D”), formerly known as
ViralexTM and

WHEREAS Norwood has the capabilities to manufacture T36D,

The Parties agree as follows:

	1. 	
      Norwood will manufacture T36D for ALDA according to
      specifications provided in Schedule “A”.

	2. 	
      ALDA will provide Norwood with the label
  designs.

	3. 	
      Norwood will assume all of the costs of manufacturing,
      except label design, and having T36D ready to ship from its warehouse in
      minimum quantities of one-half skid or 18 cases.

	4. 	
      Norwood will maintain 2 months inventory of T36D as
      specified by ALDA from time to time.

	5. 	
      ALDA will be responsible for the costs of marketing and
      sales support.

	6. 	
      ALDA will arrange for the shipping of products from
      Norwood’s warehouse to ALDA’s customers at no cost to Norwood. Norwood has
      the option to provide a quote to ALDA for shipping costs.

	7. 	
      Upon receipt of an order from ALDA, Norwood will prepare
      the required shipping documents except for shipments to Esthetics Plus for
      which ALDA Pharmaceuticals Corp. will prepare the waybills for each case
      of product and deliver the waybills to Norwood for attachment to the
      individual cases by Norwood.

	8. 	
      ALDA will set its prices according to the attached
      “ViralexTM with T3 6® Distributor Price
      List” (“the Price List”).

	9. 	
      ALDA will advise Norwood of any changes to the Price List
      45 days in advance.

	10. 	
      For each order received from ALDA, Norwood will calculate
      the value of the product being shipped from the Price List, as described
      in Paragraph 11, with the exceptions of:

		a. 	
      sales to Esthetics Plus as described in Paragraph 12
      and

		b. 	
      free samples, as described in Paragraph 13.

	11. 	
      Norwood will invoice ALDA as follows:

		a. 	
      For 480 ml. bottles, 40% of the value of the shipment
      calculated from the Price List plus GST and

		b. 	
      For 4 litre jugs, 65% of the value of the shipment
      calculated from the Price List plus GST.

	12. 	
      For shipments to Esthetics Plus, ALDA will advise
      Norwood, at the time of the shipment, of the total value of the order plus
      GST and Norwood will invoice ALDA for 65% of value of the 4 litre jugs,
      40% of the value of the 480 ml bottles plus
GST.

	13. 	
      For free samples, Norwood will invoice ALDA for Norwood’s
      cost to manufacture the free samples plus GST. ALDA will provide Norwood
      with 30 days advance notice of any intended sales promotions in which free
      samples are to be given to customers at no cost by ALDA. Norwood will
      manufacture amounts of free samples if agreed to in advance by Norwood. It
      is estimated that the quantity of free samples provided by ALDA to its
      customers will not exceed 5% of the total manufacturing of 480 ml and 4
      litre bottles of T36D undertaken in any given year by Norwood plus 10,000
      of the 60 ml sample bottles per year.

	14. 	
      ALDA will pay Norwood within 35 days after the date of
      any invoice submitted to ALDA by Norwood.

	15. 	
      In the event that Norwood sells T36D to any of its
      customers, Norwood will provide ALDA with a monthly summary of Norwood’s
      invoices showing the amount of T36D sold in each individual sale and the
      amount owed to ALDA based on ALDA receiving 35% of the value of 4 litre
      jugs and 60% of the value of 480 ml bottles, both calculated from the
      Price List, plus GST. Norwood will pay ALDA within 35 days after the date
      of any invoice provided by Norwood to Norwood’s customers.

	16. 	
      If any T36D is returned due to manufacturing defects,
      Norwood will replace the defective product with new product at Norwood’s
      cost.

	17. 	
      Norwood will have the Right of First Refusal to
      manufacture other products for ALDA under similar, but not necessarily
      identical, terms.

	18. 	
      This Agreement may be terminated:

		a. 	
      if either party provides the other party with 90 days
      written notice,

		b. 	
      by either party if there has been a breach of any
      provision of this Agreement and thirty (30) days has elapsed from the date
      that written notice has been sent to the party in breach by the other
      party or

		c. 	
      at the option of either party, if the other party becomes
      insolvent; violates the laws, regulations, rules, or statutes of any
      government; ceases doing business; makes an assignment for the benefit of
      creditors; or commits an act of bankruptcy. A failure by either party to
      exercise any right hereunder shall not operate as a waiver of such right
      and all remedies contained herein shall be
cumulative.

The terms above are accepted by:

	ALDA PHARMACEUTICALS CORP. 	 
	Per: 	 
	  	 
	“Terrance G. Owen” 	 
	Terrance G. Owen, President & CEO 	 
	  	 
	AND 	 
	  	 
	NORWOOD PACKAGING LTD. 	 
	Per: 	 
	  	 
	  	 
	“Daryl Martini” 	 
	Daryl Martini, President 	 

SCHEDULE “A”

Specifications

Cartons:

  (a) 480-ml T36® Disinfectant.
  11.75” x 8.875” x 7.50”, Kraft at least 200, Style: RSC-TAB.

  (b) Divider – interlocking for 12 bottles, Kraft Tst: 125. 

  (c) Information for labeling: 

(i) Side panels:

  The Best Available Technology 

  T36® Disinfectant 

  Hospital Grade Disinfectant 

  Limited Quantity

ALDA Pharmaceuticals Corp.

  635 Columbia Street, New Westminster, BC, V3M 1A7, Canada. 

  604-521-8300                  
  www.aldacorp.com

(ii) End panels:

  480 ml x 12

   

(d) 4-Litre T36®
  Disinfectant. 12.25” x 12.25” x 12.0”, Kraft
  Tst. at least 200, Style: RSC-TAB.

  (e) Information for labeling: 

(i) Side panels:

  The Best Available Technology 

  T36® Disinfectant 

  Hospital Grade Disinfectant 

  Limited Quantity 

ALDA Pharmaceuticals Corp.

  635 Columbia Street, New Westminster, BC, V3M 1A7, Canada. 

  604-521-8300                        
  www.aldacorp.com

(ii) End panels:

  4-Litre x 4

  

ALDA Pharmaceuticals Corp.

Caps:

  (f) 480-ml bottle, 28 mm, foil-lined cap, 28-400 white PP foil seal M1 Product
  Code 23-2105 (Richards).

  (g) 4-litre bottle, 38 mm, foil-lined cap, 23-2949 product code (Richards).

Bottles:

  (h) 480-ml, Richards Packaging Ltd. product number 51130164, (clear
  31 gms, or white 36 gms) or equivalent. 

  (i) 4-litre bottle, Richards Packaging Ltd. product number 51180034, 125 gms
  or equivalent.

Pump: Heavy-duty pump, Richards Packaging Ltd product
  number 50-1706, or equivalent. (for the 4-liter package) 

  Sprayer: Richards Packaging Ltd. product number 5910-BA, or equivalent.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]